Laddar...
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study
Emergence of new molecules acting directly on the hepatitic C virus (HCV) has improved treatment outcomes. However, there is a risk of selecting viral escape mutants, so a new combination is needed using different inhibitors that target different steps of the HCV infectious cycle. Novel single table...
Sparad:
| I publikationen: | Sci Rep |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6753069/ https://ncbi.nlm.nih.gov/pubmed/31537880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-49973-6 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|